The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
Table 4
Changes of mean uroflowmetric parameters in patients who continued the silodosin treatment ().
Parameters
0 mos.
3 mos.
6 mos.
12 mos.
18 mos.
24 mos.
30 mos.
36 mos.
42 mos.
48 mos.
(ml)
181.7
196.6
206.8
209.1
215.3
204.1
218.7
197.4
220.6
209.2
(SD)
(98.1)
(93.5)
(127.0)
(139.9)
(162.3)
(108.9)
(132.8)
(95.8)
(110.3)
(127.1)
(ml/s)
11.7
12.4
13.0
13.1
13.2
13.0
12.9
12.7
12.7
12.9
(SD)
(3.6)
(4.6)
(6.1)
(5.8)
(6.5)
(4.3)
(5.7)
(5.8)
(4.4)
(6.5)
(ml/s)
6.1
6.6
7.2
8.0
7.8
7.8
(SD)
(2.3)
(3.0)
(3.5)
(3.8)
(3.5)
(2.2)
(2.9)
(3.1)
(2.3)
(3.1)
PVR (ml)
60.4
42.6
47.2
46.3
58.1
54.2
62.6
78.7
63.3
72.4
(SD)
(70.2)
(44.0)
(38.9)
(38.2)
(48.8)
(42.3)
(49.0)
(75.6)
(34.7)
(41.5)
, , and versus baseline, the paired Student’s -test with Bonferroni correction.
